ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data

ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.

ESMO26: Roche's KRAS drug tops approved drugs in NSCLC

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met high expectations, with a head-to-head win over Lumakras and Krazati.

Moderna shares steady after ESMO data leak crash

Moderna’s share price shows signs of recovery after leaked phase 3 data for its personalised melanoma vaccine sent shares tumbling last week.